Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a cl
Is It Time To Buy AbbVie Stock At $180?
08:30am, Friday, 16'th May 2025
AbbVie (NYSE:ABBV) stock has garnered recent attention following the FDA approval of Emrelis for adults with previously treated lung cancer who exhibit an overabundance of the c-Met protein. This prot
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV
05:45am, Friday, 16'th May 2025
NEW YORK , May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a clas
The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ABBV
02:01pm, Thursday, 15'th May 2025
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer
09:46am, Thursday, 15'th May 2025
Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.
NEW YORK , May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV d
Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer
04:36pm, Wednesday, 14'th May 2025
Ongoing tariff disputes and President Trump's drug pricing order heighten uncertainties for AbbVie Inc. and Pfizer Inc. The more uncertain the time, the more investors should focus on return vectors t
AbbVie Inc. (ABBV) Presents at BofA Securities 2025 Healthcare Conference (Transcript)
03:10pm, Wednesday, 14'th May 2025
AbbVie Inc. (NYSE:ABBV ) BofA Securities 2025 Healthcare Conference May 14, 2025 1:00 PM ET Company Participants Jeff Stewart - EVP and Chief Commercialization Officer Roopal Thakkar - EVP and R&D, Ch
Calls of the Day: RobinHood, UnitedHealth, Abbvie and Lowe's
01:35pm, Wednesday, 14'th May 2025
The Investment Committee debate the latest Calls of the Day.
Lost Money on Cerevel Therapeutics Holdings, Inc. (ABBV)? Contact Levi & Korsinsky Before June 3, 2025 to Join Class Action
01:30pm, Wednesday, 14'th May 2025
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal
US FDA approves AbbVie's drug for a type of lung cancer
01:23pm, Wednesday, 14'th May 2025
The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday.
– EMRELIS is the first and only treatment approved for previously treated advanced NSCLC patients with high c-Met protein overexpression who often face poor prognosis and have limited
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:05am, Wednesday, 14'th May 2025
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.
09:55am, Wednesday, 14'th May 2025
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.
- Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA
